Global Pharma Firm Expands AGC Biologics Partnership Across Denmark and Japan, Raising Deal Value Above $560 Million

AGC Biologics has secured a commitment from an unnamed global pharmaceutical company to bring six additional commercial biologics programs to its Copenhagen site, pushing the total value of the pair's long-term manufacturing relationship beyond USD 0.56 billion.

The new allocation expands on an agreement previously anchored at AGC Biologics' Yokohama facility in Japan, where the same customer committed five commercial biologics programs to the newly opened plant.

Copenhagen Expansion Strengthens Global Biologics Manufacturing Network

With the addition of Copenhagen, the customer will run multi-product drug substance manufacturing across six biologics programs at the Danish site, spanning process transfer, scale-up, validation, and commercial production.

The two companies frame the arrangement as a consolidation of high-volume, single-use biologics manufacturing under a single global partner, spread across two continents.

Six New Programs Head to Denmark After Five Allocated to Japan

The six programs allocated to Copenhagen follow the customer's earlier decision to place five commercial biologics programs at the Yokohama facility. Together, the two commitments form the expanded agreement, which builds on an existing long-term manufacturing deal between the companies.

AGC Biologics is a contract development and manufacturing organization, and the expanded contract covers drug substance manufacturing for multiple products across the six Copenhagen programs.

The consolidation gives the customer access to what AGC Biologics describes as one of the industry's largest global networks of single-use manufacturing capacity by volume, according to BDO's bioTRAK database.

The company serves large-scale mammalian single-use manufacturing needs for major pharmaceutical companies across regions and supports customers pursuing cross-site launches, geographic flexibility, and regionalized manufacturing strategies.

Dual Submissions Underpin a Two-Continent Supply Model

Central to the deal's design is the principle that site interoperability and dual regulatory submissions unlock the benefits of local manufacturing within a global supply network.

Under the agreement, products will launch and move across facilities with several dual regulatory submissions, an approach the companies say optimizes capacity, cost, and local manufacturing benefits.

Operating multiple sites as one integrated supply node allows both parties to shift production quickly between locations as needs change. The companies state this delivers flexibility and supply chain robustness that a single-site supply arrangement could not achieve.

AGC Highlights Cross-Continental Biologics Manufacturing Flexibility

Alberto Santagostino, President and CEO of AGC Biologics, said the customer is building a more resilient, more flexible supply chain and has chosen to do so with AGC across two continents.

He said this is precisely what the company is well-positioned to offer, a market craving geographic flexibility and regionalization while retaining global supply.

Santagostino added that AGC Biologics has built its single-use strategy around quality, capacity, and deep technical expertise so that when a partner is ready to localize and scale, the company can meet them where they are.

He noted the deal takes inter-site flexibility to a larger scale and builds on existing experience, pointing out that two of the company's customers have already decided to co-launch their products from both its Seattle and Copenhagen facilities.

Repeat Allocations Read as a Signal of Network-Wide Confidence

Tadashi Murano, President of AGC Life Science Company, tied the Copenhagen allocation directly to the track record of the broader network.

He said that for a customer to bring six additional programs to Copenhagen after bringing five to Yokohama says everything about the trust the team has earned across the network.

Murano said the focus remains on building lasting, trust-based relationships with pharmaceutical customers, similar to what AGC has done for decades with industrial partners across a wide range of industries, including electronics and automotive.

The dual-site commitment also cements AGC Biologics' position as a prominent global player in single-use bioreactor manufacturing, according to the announcement.

Inside the Copenhagen Site: 18,000 Square Meters and Eight 2,000-Liter Lines

The Copenhagen expansion underpinning the new work was announced in 2024 and comprises 18,000 square meters distributed across manufacturing, quality control laboratories, and technical and warehouse areas.

The build-out includes eight 2,000-liter single-use bioreactor production lines, one 500-liter perfusion bioreactor, and two downstream purification lines.

The site's scientific teams hold 25 years of expertise in drug substance development and GMP manufacturing. Products made at Copenhagen have earned customers a total of more than 50 commercial approvals from over 20 regulatory agencies.

Why the Customer Stays Anonymous

The pharmaceutical company behind the expanded agreement is not named, consistent with standard practice in the biopharmaceutical industry.

AGC Biologics stated that customer names are not disclosed without the customer's consent and that the company regularly enters into confidential manufacturing agreements to protect customers' competitive and regulatory strategies.

Room for Further Regional Growth

Asked about the possibility of further expansion, AGC Biologics pointed to its footprint of GMP manufacturing sites across the U.S., Europe, and Asia, which it said provides capacity for customers to expand into additional regions as their commercial manufacturing needs evolve.

The company's existing network already supports cross-site launches and regionalized manufacturing strategies, as demonstrated by the Seattle and Copenhagen co-launch experience cited by its CEO.

The expanded agreement, now valued at more than USD 0.56 billion across Yokohama and Copenhagen, stands as one of the more substantial multi-site commitments in the single-use biologics manufacturing space, pairing five commercial programs in Japan with six in Denmark under a single integrated supply framework governed by dual regulatory submissions.